 |
PDBsum entry 5ngr
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Fragment-Based discovery and optimization of enzyme inhibitors by docking of commercial chemical space.
|
 |
|
Authors
|
 |
A.Rudling,
R.Gustafsson,
I.Almlöf,
E.Homan,
M.Scobie,
U.Warpman berglund,
T.Helleday,
P.Stenmark,
J.Carlsson.
|
 |
|
Ref.
|
 |
J Med Chem, 2017,
60,
8160-8169.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Fragment-based lead discovery has emerged as a leading drug development strategy
for novel therapeutic targets. Although fragment-based drug discovery benefits
immensely from access to atomic-resolution information, structure-based virtual
screening has rarely been used to drive fragment discovery and optimization.
Here, molecular docking of 0.3 million fragments to a crystal structure of
cancer target MTH1 was performed. Twenty-two predicted fragment ligands, for
which analogs could be acquired commercially, were experimentally evaluated.
Five fragments inhibited MTH1 with IC50values ranging from 6 to 79
μM. Structure-based optimization guided by predicted binding modes and analogs
from commercial chemical libraries yielded nanomolar inhibitors. Subsequently
solved crystal structures confirmed binding modes predicted by docking for three
scaffolds. Structure-guided exploration of commercial chemical space using
molecular docking gives access to fragment libraries that are several orders of
magnitude larger than those screened experimentally and can enable efficient
optimization of hits to potent leads.
|
 |
|
|
|
|
 |